Physician profile
David M Stein
NPI 1740386341
$186,087.67
in general payments reported to CMS, 2019-2025
23 companies · $35K in 2025
The $35K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $7,071 · 2021: $24K · 2022: $28K · 2023: $44K · 2024: $28K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $78K · Food and Beverage: $19K · Travel and Lodging: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $78,040.00 |
| Food and Beverage | $19,020.89 |
| Travel and Lodging | $10,096.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $66,801.16 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Abbvie INC. | $60,121.63 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $15,109.98 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $14,830.49 | 2024-2025 | Cobenfy |
| Allergan, INC. | $7,645.34 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $3,915.13 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $3,251.15 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $3,242.92 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $3,173.06 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $2,713.40 | 2020-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $1,500.10 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $992.75 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $752.28 | 2023-2025 | Auvelity, Sunosi |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $443.21 | 2019-2025 | Rexulti, Rejoyn |
| Vanda Pharmaceuticals INC. | $415.84 | 2024-2025 | Fanapt |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $330.36 | 2019-2025 | Invega Sustenna |
| Eisai INC. | $224.07 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $188.89 | 2023-2024 | Quviviq |
| Corium, LLC | $184.03 | 2022-2024 | Azstarys |
| Merck Sharp & Dohme LLC | $121.48 | 2020-2023 | Belsomra |
| Indivior INC. | $93.16 | 2023-2024 | Perseris |
| Supernus Pharmaceuticals, INC. | $22.35 | 2022 | |
| Jazz Pharmaceuticals INC. | $14.89 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.